We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




Diabetic Kidney Disease and Risk of Incident Stroke Among T2D Adults

By LabMedica International staff writers
Posted on 08 Apr 2022

Atherosclerotic cardiovascular disease (ASCVD) is a significant cause of morbidity and mortality among people with type 2 diabetes (T2D) . More...

The huge burden of ASCVD in T2D, mainly coronary artery disease (CAD) and stroke, constitutes a major public health problem in this population and accounts for significant disability and healthcare costs.

Diabetes mellitus is associated with a 3-fold greater age-adjusted risk of stroke and a higher post-stroke mortality. The increased burden of stroke in individuals with T2D is driven in large part by the high prevalence of the metabolic syndrome components in this population. However, accruing evidence suggest that other factors such as diabetes-related microvascular complications might play a role. Indeed, diabetic retinopathy was found to be associated with higher risk of stroke in people with T2D.

A team of medical scientists collaborating with those at SOVAH Health (Danville, VA, USA) included in their study a total of 9,170 participants; mean age: 62.8 ± 6.6 years, 38.2% women, 62.9% white. Of the entire sample, 62.2% of participants had no chronic kidney disease (CKD); 13.3%, CKD G1; 14.1%, CKD G2; and 10.5%, CKD G3. Urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) were assessed at baseline.

Urine microalbumin was assayed on spot urine by immunonephelometry on a BN11 nephelometer (Siemens Healthineers, Erlangen, Germany). Urinary albumin excretion was estimated as the urine albumin-to-creatinine ratio (UACR) in mg albumin/g of creatinine. eGFR was calculated in mL/min/1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Serum and urine creatinine was measured via enzymatic methods on a Roche Double Modular P Analytics automated analyzer (Roche Diagnostics, Indianapolis, IN , USA).

The scientists reported that over a median follow-up of 4.9 years, 156 participants developed a stroke (incidence rate 3.6/1,000 person-years). After adjusting for relevant confounders, higher UACR and lower eGFR were each associated with increased risk of stroke. Compared to UACR < 30 mg/g, moderate albuminuria and severe albuminuria were associated with increasing hazards for stroke (HR 1.61 and 2.29 respectively). Compared to eGFR of ≥ 60 mL/min/1.73 m2, decreased eGFR (eGFR < 60 mL/min/1.73 m2) was associated with higher risk of stroke (HR 1.50). Compared to no CKD, worsening CKD stage was associated with an increasing risk of stroke (HRs of 1.76 for CKD G1, 1.77 for CKD G2, and 2.03 for CKD G3).

The authors concluded that in a large and diverse cohort of adults with type 2 diabetes, higher UACR, decreased eGFR, and worsening CKD stages were associated with increased risk of stroke, independently of other stroke risk factors. The study was published on March 29, 2022 in the journal BMC Medicine.

Related Links:
SOVAH Health
Siemens Healthineers 
Roche Diagnostics 


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: AI-powered ctDNA analysis provides clinicians with a new lens to monitor disease evolution (Photo courtesy of Brandon Stelter, Katie Han, Kyle Smith, and Paul Northcott)

AI-Powered Liquid Biopsy Classifies Pediatric Brain Tumors with High Accuracy

Liquid biopsies offer a noninvasive way to study cancer by analyzing circulating tumor DNA in body fluids. However, in pediatric brain tumors, the small amount of ctDNA in cerebrospinal fluid has limited... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: Sophie Paczesny, M.D., Ph.D and her team have made BIOPREVENT freely available for researchers and clinician to test and learn from (Photo courtesy of Cliff Rhodes)

AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear

Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.